Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Sep 10;5:81. doi: 10.1038/s41698-021-00221-z

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — a The breakpoints for ALK with different partners; the breakpoints for ROS1 with different partners; the breakpoints for RET with different partners; the breakpoints for FGFR3 with different partners. The partners shown above the structure of each kinase belong to common partners. Some rare partners are shown under the kinase structure. The number of events involving each of the four kinases is shown to the left of each kinase structures. The percentage breakpoints with each partner, the number of events for each fusion in specific kinase breakpoints, and the total number of events for each fusion are shown. b The co-occurrence of kinase fusions and driver mutations is displayed in the hotspot plot. The incidences of driver gene mutations are shown to the left of the plot. Tissue/plasma samples were collected from 59 patients after developing resistance to EGFR TKI or fusion targeted treatment.